CMS certification 150056
Indiana University Health
1701 N Senate Blvd, Indianapolis, IN 46202
Indiana University Health has a CMS overall rating of 3 out of 5 stars. 63% of patients who answered CMS's national survey would definitely recommend it, against a US average of 71%. Of the 27 death, complication, infection and readmission measures CMS could compare, it does better than the nation on 6 and worse on 1. Emergency patients spend a median of 3 h 22 min in its emergency department before leaving (US median 2 h 42 min).
Every figure on this page is published by CMS; we arrange and explain it, and score nothing ourselves.
What patients said
Answers from patients who stayed here, collected by CMS in the national HCAHPS survey: 611 completed surveys, 15% response rate, Oct 2024 – Sep 2025.
Emergency department
How long emergency patients spent here and how some time-critical care went, from CMS's timely and effective care measures, Oct 2024 – Sep 2025. CMS classes this emergency department's patient volume as very high; busier departments tend to have longer times, so the national median for departments of the same volume is shown too. These are medians over a year of visits, not a live wait time.
| Measure | This hospital | IN | US |
|---|---|---|---|
| Median time in the emergency department before leaving Lower is better · 377 visits sampled · US median for EDs of the same volume: 3 h 21 min | 3 h 22 min | 2 h 25 min | 2 h 42 min |
| Median time for psychiatric and mental health patients Lower is better · 18 visits sampled | 5 h 48 min | 3 h 51 min | 4 h 17 min |
| Left before being seen Lower is better · 176,342 patients | 3% | 2% | 2% |
| Stroke symptoms: brain scan read within 45 minutes Higher is better · 15 patients | 87% | 71% | 69% |
| Severe sepsis and septic shock: all recommended care given Higher is better · 89 patients | 55% | 60% | 65% |
How Indiana University Health compares with nearby hospitals
The closest hospitals of the same kind that CMS rates or surveys - the same city first, then the same county and ZIP area. Every figure is CMS's: the overall star rating, the share of patients who would definitely recommend the hospital, the median time emergency patients spent before leaving, and how many death, complication, infection and readmission measures CMS found better or worse than the national rate.
| Hospital | CMS stars | Would recommend | ER median time | Vs the nation |
|---|---|---|---|---|
| Indiana University HealthThis hospital | 3/5 | 63% | 3 h 22 min | 6 better 1 worse |
| Eskenazi HealthSame city | 3/5 | 76% | 3 h 52 min | 2 better 1 worse |
| Indianapolis VA Medical CenterSame city | 3/5 | 70% | — | 3 better 1 worse |
| Community Hospital EastSame city | 3/5 | 79% | 2 h 50 min | 2 better 4 worse |
| Community Hospital South, INC.Same city | 3/5 | 79% | 3 h 16 min | 1 better 3 worse |
| Franciscan Health IndianapolisSame city | 4/5 | 77% | 3 h 32 min | 2 better 3 worse |
Hospitals differ in size and in how sick their patients are. CMS adjusts its outcome measures for that, but a star or a percentage is a starting point for questions, not a verdict. All hospitals in Indianapolis.
Deaths
How many patients died within 30 days of admission, adjusted by CMS for how sick they were. Lower is better. Data from Jul 2022 – Jun 2025.
| Measure | CMS comparison | This hospital | National |
|---|---|---|---|
| All patients, hospital-wide 6,141 cases | Too few cases | 3.3% | 3.9% |
| Heart attack 136 cases | Too few cases | 11.5% | 11.9% |
| Heart failure 325 cases | Too few cases | 10.8% | 11.1% |
| Pneumonia 457 cases | Too few cases | 14.1% | 15.2% |
| Stroke 628 cases | Too few cases | 10.7% | 11.9% |
| COPD 112 cases | Too few cases | 7% | 8.6% |
| Heart bypass surgery (CABG) 76 cases | Too few cases | 1.7% | 2.4% |
Complications
How often patients had serious complications, most of them after surgery, adjusted for how sick they were. Lower is better. Data from Jul 2022 – Jun 2024.
| Measure | CMS comparison | This hospital | National |
|---|---|---|---|
| Serious complications, combined measure | No different | 1.05 likely 0.87 – 1.23 | 1 |
| After hip or knee replacement 82 cases | Too few cases | 4.1% | 4.1% |
| Deaths after a serious but treatable surgical complication 355 cases | No different | 170.2 per 1,000 likely 138.94 per 1,000 – 201.46 per 1,000 | 173.3 per 1,000 |
| Pressure ulcers (bed sores) 11,263 cases | No different | 0.51 per 1,000 likely 0.12 per 1,000 – 0.91 per 1,000 | 0.63 per 1,000 |
| Collapsed lung caused by a procedure 13,186 cases | No different | 0.33 per 1,000 likely 0.16 per 1,000 – 0.5 per 1,000 | 0.21 per 1,000 |
| Broken bones from falls in the hospital 13,815 cases | No different | 0.24 per 1,000 likely 0.07 per 1,000 – 0.41 per 1,000 | 0.27 per 1,000 |
| Bleeding or hematoma after surgery 4,949 cases | No different | 1.89 per 1,000 likely 0.92 per 1,000 – 2.86 per 1,000 | 2.34 per 1,000 |
| Kidney injury needing dialysis after surgery 2,685 cases | No different | 2.07 per 1,000 likely 1.06 per 1,000 – 3.09 per 1,000 | 1.67 per 1,000 |
| Breathing failure after surgery 2,533 cases | No different | 12.17 per 1,000 likely 8.96 per 1,000 – 15.38 per 1,000 | 9.42 per 1,000 |
| Blood clots in the lungs or legs after surgery 5,254 cases | No different | 3.31 per 1,000 likely 2.04 per 1,000 – 4.57 per 1,000 | 3.52 per 1,000 |
| Sepsis after surgery 2,632 cases | No different | 4.96 per 1,000 likely 3.13 per 1,000 – 6.8 per 1,000 | 5.27 per 1,000 |
| Surgical wound splitting open 1,570 cases | No different | 1.78 per 1,000 likely 0.63 per 1,000 – 2.93 per 1,000 | 1.77 per 1,000 |
| Accidental cut or tear during abdominal surgery 4,418 cases | No different | 1.38 per 1,000 likely 0.74 per 1,000 – 2.02 per 1,000 | 1.06 per 1,000 |
Infections caught in the hospital
Standardized infection ratio: 1.0 means as many infections as CMS predicted for a hospital like this one. Lower is better. Data from Oct 2024 – Sep 2025.
| Measure | CMS comparison | This hospital | National |
|---|---|---|---|
| Bloodstream infections from central lines (CLABSI) | Better | 0.63 likely 0.48 – 0.82 | 1 |
| Urinary tract infections from catheters (CAUTI) | Better | 0.2 likely 0.11 – 0.33 | 1 |
| Surgical site infections after colon surgery | No different | 0.73 likely 0.45 – 1.13 | 1 |
| Surgical site infections after abdominal hysterectomy | No different | 0.37 likely 0.02 – 1.84 | 1 |
| MRSA bloodstream infections | No different | 1.05 likely 0.71 – 1.49 | 1 |
| C. diff intestinal infections | Better | 0.34 likely 0.27 – 0.43 | 1 |
Readmissions and return visits
How often patients had to come back to a hospital after going home. Lower is better. Data from Jul 2023 – Jun 2025.
| Measure | CMS comparison | This hospital | National |
|---|---|---|---|
| Readmitted after a heart attack 267 cases | Too few cases | 12.7% | 14.4% |
| Readmitted after heart failure 728 cases | Too few cases | 17.7% | 21.3% |
| Readmitted after pneumonia 864 cases | Too few cases | 17.1% | 17.3% |
| Readmitted after COPD 291 cases | Too few cases | 18.9% | 20% |
| Readmitted after heart bypass surgery 100 cases | Too few cases | 10.1% | 11% |
| Readmitted after hip or knee replacement 74 cases | Too few cases | 6.4% | 5.8% |
| Days back in hospital after a heart attack 169 cases | Too few cases | -18 days per 100 | — |
| Days back in hospital after heart failure 408 cases | Too few cases | 9.6 days per 100 | — |
| Days back in hospital after pneumonia 500 cases | Too few cases | 13.9 days per 100 | — |
| Unplanned visits after an outpatient colonoscopy 210 cases | No different | 13 per 1,000 likely 9.7 per 1,000 – 17.8 per 1,000 | 13 per 1,000 |
| Hospital admissions during outpatient chemotherapy 877 cases | No different | 9.4 per 100 likely 7.8 per 100 – 11.5 per 100 | 10.7 per 100 |
| ER visits during outpatient chemotherapy 877 cases | No different | 5 per 100 likely 3.9 per 100 – 6.5 per 100 | 5.4 per 100 |
| Unplanned visits after outpatient surgery 1,074 cases | No different | 0.9 likely 0.7 – 1.1 | — |
1 more measure had too few cases here to report.
Clinicians registered at this address
1,045 clinicians give this hospital's street address as their practice location in NPPES, the federal provider registry, plus 50 residents and trainees. The same address can take in offices and clinics in the building, and a listing does not prove admitting privileges or current employment.
| Specialty | Clinicians |
|---|---|
| Emergency Medicine | 214 |
| Anesthesiology | 143 |
| Diagnostic Radiology | 75 |
| Pharmacist | 53 |
| Family | 48 |
| Internal Medicine | 47 |
| Physician Assistant | 40 |
| Anesthesiologist Assistant | 38 |
| Acute Care | 26 |
| Nurse Anesthetist, Certified Registered | 22 |
| Gerontology | 21 |
| Gastroenterology | 19 |
First 12 alphabetically
Money from drug and device companies
Drug and device makers have to report what they pay teaching hospitals to CMS's Open Payments program. At many teaching hospitals most of it is research funding, or royalties for inventions the hospital licensed to a company. A payment on its own does not show a conflict of interest.
- 2019 $3M
- 2020 $1.3M
- 2021 $1.1M
- 2022 $4.3M
- 2023 $2.3M
- 2024 $7.2M
- 2025 $1.8M
What the 2025 general payments were for
| Type of payment | Amount | Payments |
|---|---|---|
| Grants | $259,124 | 4 |
| Medical devices and supplies on long-term loan | $103,120 | 9 |
| Speaking, teaching and other services | $62,560 | 8 |
| Debt forgiveness | $62,437 | 22 |
| Space rental and facility fees | $44,531 | 16 |
| Education | $18,371 | 1 |
| Consulting fees | $8,601 | 2 |
| Food and beverage | $89 | 1 |
Largest paying companies, 2025
| Company | Amount | Payments |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | $358,025 | 77 |
| Merck Sharp & Dohme LLC | $264,134 | 8 |
| Gilead Sciences, Inc. | $259,124 | 4 |
| Eli Lilly and Company | $187,249 | 2 |
| Janssen Research & Development, LLC | $95,515 | 56 |
| Medtronic, Inc. | $75,496 | 16 |
| AngioDynamics, Inc. | $73,333 | 2 |
| United Therapeutics Corporation | $51,890 | 19 |
Largest research studies funded here, 2025
| Study | Amount |
|---|---|
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCUL… Eli Lilly and Company · NCT06292013 | $162,448 |
| A Phase 3 Randomized Open-Label Study of Adjuvant Pembrolizumab With or Without MK-2870 in Participants With Resectable Stage II to IIIB N2 NSCLC not… Merck Sharp & Dohme LLC | $101,192 |
| A Phase 2, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effects of Sotatercept versus Placebo for the Treatment of Combined Pos… Merck Sharp & Dohme LLC | $90,060 |
| STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION… Takeda Pharmaceuticals U.S.A., Inc. | $83,557 |
| A Randomized, Double-blind, Placebo-Controlled Phase 3b Study to Evaluate the Short- and Long-term Efficacy and Safety of Dual Targeted Therapy With… Takeda Pharmaceuticals U.S.A., Inc. | $79,058 |
| A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral … Janssen Research & Development, LLC | $63,913 |
| TAK-999-3002 A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Fazirsiran in the Treatment of Alph… Takeda Pharmaceuticals U.S.A., Inc. | $62,101 |
| A PHASE 4, PROSPECTIVE, MULTICENTER, SINGLE-ARM STUDY OF A MEAN PULMONARY ARTERY PRESSURE-TARGETED APPROACH WITH EARLY AND RAPID TREPROSTINIL THERAPY… United Therapeutics Corporation · NCT05203510 | $51,890 |
Amounts are as the paying companies reported them to CMS; Open Payments data retrieved 13 Sep 2026. Full record on CMS Open Payments.
How to read this page
- Everything here is published by CMS on Care Compare. We arrange it and explain it; the star ratings and the better / worse verdicts are CMS's, not ours.
- “No different” is the most common result on most measures at most hospitals. CMS only calls a result better or worse when the difference from the national rate is statistically clear.
- Death, complication and readmission rates are adjusted by CMS for how sick patients were, so hospitals that treat sicker patients can be compared fairly.
- Infection results are ratios: 1.0 means as many infections as CMS predicted for a hospital like this one, below 1.0 is fewer.
- These are hospital-wide results. They do not rate an individual doctor, nurse or department, and they are not medical advice.
CMS Care Compare data retrieved 4 Oct 2026, refreshed weekly. Where this data comes from and how we handle it · Report an error
Common questions about Indiana University Health
Is Indiana University Health a good hospital?
Indiana University Health has a CMS overall rating of 3 out of 5 stars. Of the 27 death, complication, infection and readmission measures CMS could compare, it does better than the nation on 6 and worse on 1. These are hospital-wide results published by CMS; they do not rate individual doctors or departments.
Would patients recommend Indiana University Health?
63% of patients who answered CMS's national survey would definitely recommend it, against a US average of 71%. The figure comes from 611 completed HCAHPS surveys.
How long is the wait in the Indiana University Health emergency room?
Emergency patients spend a median of 3 h 22 min in its emergency department before leaving (US median 2 h 42 min). Among US emergency departments with very high patient volume, like this one, the median is 3 h 21 min. 3% of emergency patients left before being seen (US 2%). These are medians over a year of visits, not a live wait time.
Does Indiana University Health receive money from drug and device companies?
Drug and device makers reported $1.8M in payments to Indiana University Health for 2025, most of it research funding, under the federal Open Payments program. A payment on its own does not show a conflict of interest.